dc.contributor.author | Patarroyo, Manuel-Alfonso | |
dc.contributor.author | Patarroyo, Manuel-Elkin | |
dc.contributor.author | Pabón, Laura | |
dc.contributor.author | Alba, Martha patricia | |
dc.contributor.author | Bermúdez, Adriana | |
dc.contributor.author | Rugeles, María Teresa | |
dc.contributor.author | Díaz-Arevalo, Diana | |
dc.contributor.author | Zapata, María Isabel | |
dc.contributor.author | Reyes, César | |
dc.contributor.author | Suárez, Carlos F. | |
dc.contributor.author | Agudelo, William | |
dc.contributor.author | Zapata, Wildeman | |
dc.date.accessioned | 2022-08-10T18:46:55Z | |
dc.date.available | 2022-08-10T18:46:55Z | |
dc.date.issued | 2022 | |
dc.identifier.citation | Patarroyo, M. A., Patarroyo, M. E., Pabón, L., Alba, M. P., Bermudez, A., Rugeles, M. T., . . . Avendaño, C. (2022). SM-COLSARSPROT: Highly immunogenic supramutational synthetic peptides covering the World’s population. Frontiers in Immunology, 13 doi:10.3389/fimmu.2022.859905 | spa |
dc.identifier.issn | 1664-3224 | spa |
dc.identifier.uri | https://repository.udca.edu.co/handle/11158/4811 | |
dc.description.abstract | Fifty ~20–amino acid (aa)–long peptides were selected from functionally relevant SARS-CoV-2 S, M, and E proteins for trial B-21 and another 53 common ones, plus some new ones derived from the virus’ main genetic variants for complementary trial C-21. Peptide selection was based on tremendous SARS-CoV-2 genetic variability for analysing them concerning vast human immunogenetic polymorphism for developing the first supramutational, Colombian SARS-protection (SM-COLSARSPROT), peptide mixture. Specific physicochemical rules were followed, i.e., aa predilection for polyproline type II left-handed (PPIIL) formation, replacing β-branched, aromatic aa, short-chain backbone H-bond-forming residues, π-π interactions (n→π* and π-CH), aa interaction with π systems, and molecular fragments able to interact with them, disrupting PPIIL propensity formation. All these modified structures had PPIIL formation propensity to enable target peptide interaction with human leukocyte antigen-DRβ1* (HLA-DRβ1*) molecules to mediate antigen presentation and induce an appropriate immune response. Such modified peptides were designed for human use; however, they induced high antibody titres against S, M, and E parental mutant peptides and neutralising antibodies when suitably modified and chemically synthesised for immunising 61 major histocompatibility complex class II (MHCII) DNA genotyped Aotus monkeys (matched with their corresponding HLA-DRβ1* molecules), predicted to cover 77.5% to 83.1% of the world’s population. Such chemically synthesised peptide mixture represents an extremely pure, stable, reliable, and cheap vaccine for COVID-19 pandemic control, providing a new approach for a logical, rational, and soundly established methodology for other vaccine development. | eng |
dc.format.mimetype | application/pdf | spa |
dc.language.iso | eng | spa |
dc.rights | https://creativecommons.org/licenses/by-nc-sa/4.0/legalcode.es | eng |
dc.rights.uri | https://creativecommons.org/licenses/by-nc-sa/4.0/ | spa |
dc.source | https://www.frontiersin.org/articles/10.3389/fimmu.2022.859905/full | spa |
dc.title | SM-COLSARSPROT: Highly Immunogenic Supramutational Synthetic Peptides Covering the World’s Population | eng |
dc.type | Artículo de revista | spa |
dc.rights.accessrights | info:eu-repo/semantics/openAccess | spa |
dc.rights.license | Atribución-NoComercial-CompartirIgual 4.0 Internacional (CC BY-NC-SA 4.0) | spa |
dc.description.notes | Incluye referencias bibliográficas. | spa |
dc.identifier.doi | 10.3389/fimmu.2022.859905 | |
dc.type.coar | http://purl.org/coar/resource_type/c_2df8fbb1 | spa |
dc.type.driver | info:eu-repo/semantics/article | spa |
dc.type.version | info:eu-repo/semantics/publishedVersion | spa |
dc.subject.agrovoc | Péptidos sintéticos | |
dc.subject.agrovoc | Coronavirus del síndrome respiratorio agudo grave 2 | |
dc.subject.agrovoc | Variantes | |
dc.relation.indexed | N/A | spa |
dc.relation.citationedition | (May., 2022) Artículo Número 859905 | spa |
dc.relation.citationendpage | 23 | spa |
dc.relation.citationstartpage | 1 | spa |
dc.relation.citationvolume | 13 | spa |
dc.relation.ispartofjournal | Frontiers in Immunology | spa |
dc.type.content | Text | spa |
dc.type.redcol | http://purl.org/redcol/resource_type/ART | spa |
oaire.accessrights | http://purl.org/coar/access_right/c_abf2 | spa |
dc.type.coarversion | http://purl.org/coar/version/c_970fb48d4fbd8a85 | spa |